×

Merck raises 2026 profit guidance, beats quarterly estimates

By Thomson Reuters Aug 6, 2026 | 12:36 AM

By Ludwig Burger, Patricia Weiss and Ozan Ergenay

FRANKFURT, Aug 6 (Reuters) – Germany’s Merck KGaA raised its 2026 core profit guidance and beat quarterly expectations on Thursday, helped by ​continued strong demand for semiconductor materials and drug production ‌supplies.

The diversified family-controlled group said it expects adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of between 5.9 billion euros and 6.3 billion euros ($6.8 billion-$7.3 billion) in 2026, up from previous guidance of between 5.7 billion euros and ‌6.1 ​billion euros.

Quarterly adjusted EBITDA rose 9.4% ⁠to 1.60 billion euros, above ⁠analysts’ average estimate of 1.53 billion euros, according to a company-provided poll.

CEO Kai Beckmann told reporters that growing AI-related spending is a driver of the company’s semiconductor business.

As a supplier ​to the semiconductor industry, Merck manufactures specialty materials and chemical solutions used to produce advanced microchips that underpin AI applications and ⁠data centres.

Beckmann said demand remained strong, ⁠with customers continuing to report capacity bottlenecks for ​AI-related technologies.

He added that Merck raised its 2026 guidance based on ​robust operating performance and easing foreign exchange headwinds.

Shares in Merck, ‌which have gained almost 20% since the start of the year, were up around 1% as of 0936 GMT.

Analysts at Jefferies said Merck delivered a strong quarterly report and added that they ⁠expect investors to welcome the guidance hike.

“Given the strong set of results and FY guidance upgrade, we expect the shares to outperform by ⁠a couple of percentage ‌points,” analysts at J.P. Morgan said.

In June, ⁠Merck boosted its Life Science unit, which makes ​drug research ‌and manufacturing tools, by striking an $11.3 billion ​deal to buy ⁠Bio-Techne, its biggest transaction in more than a decade.

“The proposed acquisition of Bio-Techne would add additional differentiated capabilities across research, bioprocessing and advanced therapeutics,” Merck said on Thursday.

($1 = 0.8660 euros)

(Reporting by Ludwig Burger, Patricia Weiss and Ozan Ergenay; Editing by Linda Pasquini, Janane Venkatraman ​and Matt Scuffham)